Condition: Sarcomatoid Carcinoma of Lung · Sponsor: Qian Chu
This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab and famitinib . Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody, and famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.
This description comes directly from the study's public registry record.
Qian Chu · 13212760751 · qianchu@163.com
Lin Wu · 13170419973 · wulin-calf@vip.163.com
Always discuss trial participation with your own doctor first.
| The first Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Active Not Recruiting |
| Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Henan Provincial People's Hospital | Zhengzhou, Henan, China | Recruiting |
| Qian Chu | Wuhan, Hubei, China | Recruiting |
| Hubei Cancer Hospital | Wuhan, Hubei, China | Recruiting |
| Renmin Hospital of Wuhan University Hubei General Hospital | Wuhan, Hubei, China | Recruiting |
| The Second Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| The First Affiliated Hospital of Shandong First Medical University | Jinan, Shandong, China | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04888429